Terminal extramedullary conus spinal cord lipoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:645288
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Terminal extramedullary conus spinal cord lipoma is a rare congenital spinal dysraphism characterized by a lipomatous (fatty) mass located at the terminal end of the spinal cord (conus medullaris) but situated outside the medullary tissue itself. Unlike intradural lipomas that infiltrate the substance of the spinal cord, this type of lipoma is attached to the terminal conus or filum terminale without significant invasion into the neural tissue. It is classified among closed spinal dysraphisms (occult spinal dysraphisms), meaning the overlying skin is typically intact, though cutaneous stigmata such as a subcutaneous lipoma, skin dimple, or hairy patch may be present over the lower back. This condition primarily affects the nervous system, specifically the lumbosacral spinal cord and associated nerve roots. The lipoma can cause tethering of the spinal cord, restricting its normal movement within the spinal canal. As a child grows, this tethering may lead to progressive neurological symptoms including lower extremity weakness, gait abnormalities, sensory changes in the legs and perineal region, back or leg pain, and bladder or bowel dysfunction (neurogenic bladder or bowel). Orthopedic manifestations such as foot deformities (e.g., pes cavus, equinovarus) or scoliosis may also develop. Symptoms may present in infancy or childhood, though some patients remain asymptomatic until later in life. Diagnosis is typically made through magnetic resonance imaging (MRI) of the spine, which can delineate the lipoma and its relationship to the conus medullaris and surrounding neural structures. Management depends on the presence and severity of symptoms. Surgical intervention, usually involving untethering of the spinal cord and debulking of the lipoma, is considered when neurological deterioration is evident or anticipated. The goal of surgery is to prevent further neurological decline rather than to reverse existing deficits. Prophylactic surgery in asymptomatic patients remains a topic of clinical debate. Long-term urological and neurological follow-up is recommended, as retethering can occur after surgical intervention.

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Terminal extramedullary conus spinal cord lipoma.

View clinical trials →

No actively recruiting trials found for Terminal extramedullary conus spinal cord lipoma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Terminal extramedullary conus spinal cord lipoma community →

No specialists are currently listed for Terminal extramedullary conus spinal cord lipoma.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Terminal extramedullary conus spinal cord lipoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Terminal extramedullary conus spinal cord lipomaForum →

No community posts yet. Be the first to share your experience with Terminal extramedullary conus spinal cord lipoma.

Start the conversation →

Latest news about Terminal extramedullary conus spinal cord lipoma

No recent news articles for Terminal extramedullary conus spinal cord lipoma.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Terminal extramedullary conus spinal cord lipoma

What is Terminal extramedullary conus spinal cord lipoma?

Terminal extramedullary conus spinal cord lipoma is a rare congenital spinal dysraphism characterized by a lipomatous (fatty) mass located at the terminal end of the spinal cord (conus medullaris) but situated outside the medullary tissue itself. Unlike intradural lipomas that infiltrate the substance of the spinal cord, this type of lipoma is attached to the terminal conus or filum terminale without significant invasion into the neural tissue. It is classified among closed spinal dysraphisms (occult spinal dysraphisms), meaning the overlying skin is typically intact, though cutaneous stigmata

How is Terminal extramedullary conus spinal cord lipoma inherited?

Terminal extramedullary conus spinal cord lipoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.